The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.
Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry’s commitment to improving patient outcomes while reducing procedural risks.
The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.
With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women’s reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.
This product will be delivered within 1-3 business days.
Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry’s commitment to improving patient outcomes while reducing procedural risks.
The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.
With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women’s reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.
U.S. Uterine Fibroids Treatment Devices Market Report Segmentation
- Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.
- Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.
- In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Uterine Fibroids Treatment Devices Market Variables, Trends, & Scope
Chapter 4. U.S. Uterine Fibroids Treatment Devices Market: Technology Estimates & Trend Analysis
Chapter 5. U.S. Uterine Fibroids Treatment Devices Market: Mode of Treatment Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic
- Stryker
- Boston Scientific Corporation
- Insightec.
- CooperSurgical Inc.
- Hologic, Inc.
- CONMED Corporation.
- Merit Medical Systems.
- Minerva Surgical, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | March 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.77 Billion |
| Forecasted Market Value ( USD | $ 4.71 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
